专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090239791A1 PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC SUBSTANCE WHICH INHIBITS IL-2 PRODUCTION 审中-公开
标题翻译：含有抑制IL-2生产的脂质物质的药物组合物
公开(公告)号：US20090239791A1
公开(公告)日：2009-09-24
申请号：US12256851
申请日：2008-10-23
申请人： Takayuki Yoshida , Kiyo Nakanishi , Atsushi Maeda , Kazuhiro Sako , Yuki Kasashima , Hiromu Kondo , Tatsunobu Yoshioka , Yuuki Tsutsui
发明人： Takayuki Yoshida , Kiyo Nakanishi , Atsushi Maeda , Kazuhiro Sako , Yuki Kasashima , Hiromu Kondo , Tatsunobu Yoshioka , Yuuki Tsutsui
IPC分类号： A61K38/13 , A61K31/436 , A61K31/343
CPC分类号： A61K9/08 , A61K31/343 , A61K31/365 , A61K31/436 , A61K38/13 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/44
摘要： A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can develop desired pharmacological effects.
摘要翻译：公开了一种药物组合物，其包含抑制IL-2产生的亲脂性物质，以及能够抑制物质的血液暴露并将其输送到口服给药后的淋巴液的碱。药物组合物可以抑制物质的血液暴露以减少其不利影响，并且可以产生所需的药理作用。

2. 发明授权

US07008640B2 Pharmaceutical composition for oral use with improved absorption 失效
公开(公告)号：US07008640B2
公开(公告)日：2006-03-07
申请号：US09907557
申请日：2001-07-16
申请人： Shunsuke Watanabe , Shigeo Takemura , Yuuki Tsutsui , Hiromu Kondo , Kiyo Nakanishi , Kazuhiro Sako , Toyohiro Sawada
发明人： Shunsuke Watanabe , Shigeo Takemura , Yuuki Tsutsui , Hiromu Kondo , Kiyo Nakanishi , Kazuhiro Sako , Toyohiro Sawada
IPC分类号： A61K9/54 , A61K9/48 , A61K9/20 , A61K9/14 , A61K9/16
CPC分类号： A61K9/2027 , A61K9/2846 , A61K9/2853 , A61K9/2893 , A61K31/65 , A61K31/663 , A61K47/12 , A61K47/32
摘要： The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.

3. 发明授权

US08128958B2 Sustained release pharmaceutical composition 失效
标题翻译：持续释放药物组合物
公开(公告)号：US08128958B2
公开(公告)日：2012-03-06
申请号：US10843005
申请日：2004-05-10
申请人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K9/20 , A61K9/16 , A61K9/22 , A61K9/50 , A01N41/06 , C07C303/00
CPC分类号： A61K31/18
摘要： The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.
摘要翻译：本发明提供一种缓释药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体以及血浆中坦索罗辛浓度的比（Cmin / Cmax比）给药后每小时制剂24小时（Cmin）至给药后的最大血浆坦洛新浓度（Cmax）为约0.4以上。

4. 发明申请

US20050100603A1 Sustained release pharmaceutical composition 失效
标题翻译：持续释放药物组合物
公开(公告)号：US20050100603A1
公开(公告)日：2005-05-12
申请号：US10843005
申请日：2004-05-10
申请人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K9/00 , A61K9/06 , A61K9/16 , A61K9/22 , A61K9/26 , A61K9/34 , A61K31/18
CPC分类号： A61K31/18
摘要： [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an α1 receptor blocking action are reduced. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.
摘要翻译： [问题]与目前已经提供给医疗环境的目前含有盐酸坦索罗辛的口服缓释制剂相比，需要提供一种缓释药物组合物，其功效相当于甚至更好，不良事件如不良反应（例如，姿势低血压）降低，可以增加剂量，并且如果需要，食物的摄入不限于剂量，并且还需要提供一种施用盐酸坦洛新的方法，其中不良反应伴随着基于α1受体阻断作用的治疗或预防。 [解决方法]一种持续释放药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，其比例（C min / 给药后24小时血浆坦索罗辛浓度与给药后的最大血浆坦索罗辛浓度（C ）相比较，差异有统计学意义（C < SUB> max ）为约0.4以上。

5. 发明申请

US20120088838A1 METHODS FOR MAINTAINING EFFECTIVE PLASMA CONCENTRATIONS OF A PHARMACEUTICAL 审中-公开
标题翻译：维持药物有效等离子体浓度的方法
公开(公告)号：US20120088838A1
公开(公告)日：2012-04-12
申请号：US13329164
申请日：2011-12-16
申请人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K31/18 , A61P13/02 , A61P13/08
CPC分类号： A61K31/18
摘要： The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.
摘要翻译：本发明提供一种缓释药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，血浆坦洛新浓度的比（Cmin / Cmax比）为24 给药后每小时制剂（Cmin）至给药后最大血浆坦洛新浓度（Cmax）约为0.4或更高的小时。

6. 发明申请

US20110281906A1 SUSTAINED RELEASE FORMULATION FOR TACROLIMUS 审中-公开
标题翻译：持续发布TACROLIMUS公式
公开(公告)号：US20110281906A1
公开(公告)日：2011-11-17
申请号：US13195889
申请日：2011-08-02
申请人： Hiromu Kondo , Hiroyuki Kojima , Keiichi Yoshihara , Yuko Taketani , Takuya Ishii
发明人： Hiromu Kondo , Hiroyuki Kojima , Keiichi Yoshihara , Yuko Taketani , Takuya Ishii
IPC分类号： A61K31/436 , A61P43/00
CPC分类号： A61K9/2054 , A61K9/2018 , A61K9/2031 , A61K31/436
摘要： A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.
摘要翻译：一种用于他克莫司的缓释药物组合物，其包含含有他克莫司或其药学上可接受的盐的固体分散体和用于缓释药物组合物的载体，其中在溶出试验开始后4小时后他克莫司的溶出速率小于 35％被披露。

7. 发明申请

US20080131511A1 Pharmaceutical Composition for Treatment of Tear and Salivary Fluid Drying 审中-公开
标题翻译：用于治疗泪液和唾液流体干燥的药物组合物
公开(公告)号：US20080131511A1
公开(公告)日：2008-06-05
申请号：US11861725
申请日：2007-09-26
申请人： Yohei Okada , Ken Ikeda , Fumikazu Wanibuchi , Keiichi Yoshihara , Hiromu Kondo , Hiroyuki Kojima
发明人： Yohei Okada , Ken Ikeda , Fumikazu Wanibuchi , Keiichi Yoshihara , Hiromu Kondo , Hiroyuki Kojima
IPC分类号： A61K9/00 , A61K31/407 , A61P1/02 , A61P27/02 , A61P43/00
CPC分类号： C07D491/107 , A61K31/438
摘要： [Problem] An agent for treating eye and mouth dryness, which does not accompanies undesirable actions is provided.[Means for Resolution] Administration of the compound A made it possible to accelerate tear and salivary fluid secretion without accompanying sweating and its sustained release administration enabled acceleration of lacrimal gland and salivary gland cell growth as well.
摘要翻译： [问题]提供了不伴随不良作用的治疗眼睛和口腔干燥的药剂。 [解决方法]化合物A的给药使得可以加速泪液和唾液分泌而不伴随出汗，并且其持续释放给药使得能够加速泪腺和唾液腺细胞生长。

8. 发明申请

US20090011018A1 Sustained release formulation for tacrolimus 审中-公开
标题翻译：他克莫司的缓释制剂
公开(公告)号：US20090011018A1
公开(公告)日：2009-01-08
申请号：US12003472
申请日：2007-12-26
申请人： Hiromu Kondo , Hiroyuki Kojima , Keiichi Yoshihara , Yuko Taketani , Takuya Ishii
发明人： Hiromu Kondo , Hiroyuki Kojima , Keiichi Yoshihara , Yuko Taketani , Takuya Ishii
IPC分类号： A61K31/436 , A61K9/24 , A61K9/00 , A61P37/06
CPC分类号： A61K9/2054 , A61K9/2018 , A61K9/2031 , A61K31/436
摘要： A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.
摘要翻译：一种用于他克莫司的缓释药物组合物，其包含含有他克莫司或其药学上可接受的盐的固体分散体和用于缓释药物组合物的载体，其中在溶出试验开始后4小时后他克莫司的溶出速率小于 35％被披露。

9. 发明申请

US20080181947A1 Controlled release dosage form of tacrolimus 审中-公开
标题翻译：他克莫司的控释剂型
公开(公告)号：US20080181947A1
公开(公告)日：2008-07-31
申请号：US11902751
申请日：2007-09-25
申请人： Hiroyuki Kojima , Hiromu Kondo , Keiichi Yoshihara , Yuko Taketani , Takuya Ishii
发明人： Hiroyuki Kojima , Hiromu Kondo , Keiichi Yoshihara , Yuko Taketani , Takuya Ishii
IPC分类号： A61K9/22 , A61K31/436
CPC分类号： A61K9/146 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/2086 , A61K9/2846 , A61K31/436 , A61K47/32 , A61K47/36 , A61K47/38
摘要： A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is disclosed. The controlled release dosage form of tacrolimus has an excellent controlled release and shows a stable blood concentration.
摘要翻译：他克莫司的控释剂量形式，其包含他克莫司的固体分散体，其中控释片基选自水溶性大分子，胶基和成膜剂，并且不形成固体进一步包含他克莫司的分散体。他克莫司的控制释放剂量具有优异的控制释放并显示稳定的血液浓度。

10. 发明申请

US20070105934A1 Pharmaceutical composition for treatment of tear and salivary fluid drying 审中-公开
标题翻译：用于治疗泪液和唾液流体干燥的药物组合物
公开(公告)号：US20070105934A1
公开(公告)日：2007-05-10
申请号：US10578682
申请日：2005-10-04
申请人： Yohei Okada , Ken Ikeda , Fumikazu Wanibuchi , Keiichi Yoshihara , Hiromu Kondo , Hiroyuki Kojima
发明人： Yohei Okada , Ken Ikeda , Fumikazu Wanibuchi , Keiichi Yoshihara , Hiromu Kondo , Hiroyuki Kojima
IPC分类号： A61K31/407
CPC分类号： C07D491/107 , A61K31/438
摘要： [Problem]An agent for treating eye and mouth dryness, which does not accompanies undesirable actions is provided. [Means for Resolution]Administration of the compound A made it possible to accelerate tear and salivary fluid secretion without accompanying sweating and its sustained release administration enabled acceleration of lacrimal gland and salivary gland cell growth as well.
摘要翻译： [问题]提供了不伴随不良作用的治疗眼睛和口腔干燥的药剂。 [解决方法]化合物A的给药使得可以加速泪液和唾液分泌而不伴随出汗，并且其持续释放给药使得能够加速泪腺和唾液腺细胞生长。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式